Mr. Aras Azadian reports

AVICANNA LAUNCHES MYMEDI.CA INTEGRATED HEALTHCARE PROGRAM IN CANADA

Avicanna Inc. has established the MyMedi.ca Integrated Healthcare Program, which is designed to integrate medical cannabis care and patient support into Canadian health care institutions and clinical networks.

The program extends the MyMedi.ca platform beyond traditional medical cannabis and referral channels and is intended to support hospitals, specialty clinics, multidisciplinary healthcare networks, insurers and other health care organizations seeking to incorporate structured medical cannabis pathways into their existing models of care. The program extends access to a focused medical cannabis formulary, pharmacist-led patient support, health care provider (HCP) treatment planning and education as well as reimbursement and insurance.

"An important next step in the evolution of medical cannabis is furthering integration and access within established health care environments," said Aras Azadian, chief executive officer of Avicanna. "Building on a decade of research and collaboration with the Canadian medical community, this new program further supports hospitals, clinics and health care networks, with the specialized infrastructure and support to incorporate medical cannabis into existing models of care. For patients, this opens additional access to HCP-led care, individualized treatment support and insurance coverage with the aim of improving treatment outcomes."

Building on MyMedi.ca's established infrastructure and proven healthcare integration

The program builds on Avicanna's work with leading Canadian hospitals, health care institutions, and medical professionals on clinical research and cannabinoid access. This includes the Sunnybrook Odette Cancer Centre pilot, which brought medical cannabis support into an established oncology setting and helped refine the patient pathways, educational frameworks and support models behind the program.

About Avicanna Inc.

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including research and development and clinical development leading to the commercialization of more than 30 proprietary, evidence-based finished products and supporting four commercial-stage business pillars.

We seek Safe Harbor.